On July 19, 2018, the U.S. District Court, Northern District of California, denied a permanent injunction requested by Illumina, Inc, and instead ruled that a forward looking royalty for continued non-voluntary use of the invention, a type of compulsory license,… Continue Reading →
On Thursday February 7, 2019, KEI submitted comments and intent to testify at the hearing for the 2019 US Trade Representative’s Special 301 review process. This year’s hearing will take place on Wednesday February 27, 2019 at the Office of… Continue Reading →
On June 8, 2018 the Cámara de Diputados of the Chilean Congress overwhelmingly passed a resolution calling on the Ministry of Health to proceed with compulsory licenses on patents covering hepatitis C virus (HCV) drugs. Resolution No. 68, passed with… Continue Reading →
KEI has joined unions, NGOs and payors on a letter sent to Senator Grassley and Sen. Feinstein, the chair and ranking member of the Judiciary Committee, thanking them for their support of the Creating and Restoring Equal Access to Equivalent… Continue Reading →
KEI submitted a post-hearing submission to the USTR for the Special 301 on behalf of itself and twelve other international NGOs and academic institutions condemning recent pressures on Colombia’s legal and regulatory measures to increase access to affordable medicines, including… Continue Reading →
The 2010 Fabrazyme NIH Bayh-Dole march-in case https://www.keionline.org/cl/bayh-dole/fabrazyme The 2014 FTC complaint regarding collusion between Shire and Sanofi. https://www.keionline.org/22538
Representative Ro Khanna (D-CA-17) was joined by 17 other members of Congress in calling upon Department of Health and Human Services Secretary Alex Azar to issue a compulsory license on patents for medications to treat hepatitis C, by exercising 28… Continue Reading →
To be added, the early CLs on HIV drugs in several African countries. South Africa 2013 2003: CPTech’s 2003 reports for the RSA Competition Commission, in Hazel Tau et al.v GSK, Boehringer, et al. CPTech was the consultant to the… Continue Reading →
India 2010 2010: India’s intervention to the WTO TRIPS Council: TRIPS plus enforcement trends, 2010-06-10 2011 2011: Karl De Gucht writes Andris Piebalgs on topic of European Union IPR demands on India and other developing countries, 2011-05-28 2011: WTO TRIPS… Continue Reading →
Brazil 1990-2000 Comments for the Working Group On Intellectual Property Rights, Third Trade Ministerial and Americas Business Forum, Belo Horizonte, Brazil, May 13-16,1997, 1997-05-16 2005 U.S. DoS Cable: U.S. PHARMA FIRMS THREATENED WITH LICENSING (Brazil), June 3, 2005. U.S. DoS… Continue Reading →